Document is current
Any future updates will be listed below
-
Authors
Beckerman, Rachel
Gori, Andrea
Jeyakumar, Sushanth
Malin, Jakob J.
Paredes, Roger
Póvoa, Pedro
Smith, Nathaniel J.
Teixeira-Pinto, Armando
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 7 March 2022
Accepted: 3 May 2022
First Online: 10 June 2022
Competing interests
: AG has received research grants, advisory board fees, and travel grants from Angelini, Menarini, Gilead Sciences, Janssen, MSD, Novarti, Pfizer, ViiV, and GSK. JJM received consulting fees from Maple Health Group and Atriva Therapeutics GmbH, reimbursements for travel expenses from Gilead Sciences, ViiV Healthcare and Correvio Pharma, institutional research funding from the National Institutes of Health. PP has research grants, advisory boards fees from Technophage, MSD, Abionic and Gilead Sciences. RP has received research support (awarded to his institution) and participated in advisory boards from Gilead, ViiV Healthcare, MSD, Lilly and Theratechnologies. RB, SJ, RP, MJS and ATP have no competing interests to declare.
